Telavancin contraindications: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Telavancin}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIBATIV (TELAVANCIN HYDROCHLORIDE) INJECTION...") |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Contraindications== | |||
None.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIBATIV (TELAVANCIN HYDROCHLORIDE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e7c066c-0950-47ce-899d-76881d80c492 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIBATIV (TELAVANCIN HYDROCHLORIDE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e7c066c-0950-47ce-899d-76881d80c492 | publisher = | date = | accessdate = }}</ref> | |||
Latest revision as of 23:26, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Contraindications
None.[1]
References
Adapted from the FDA Package Insert.